CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

John Maraganore

Former CEO, Alnylam

Search every verified John Maraganore interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. John Maraganore, the founding CEO of Alnylam Pharmaceuticals, has remained active in the biotech industry as an investor, advisor, and commentator. In 2025, he co-founded and became co-CEO of Corsera Health, a venture focused on developing an RNAi-based drug for cardiovascular disease prevention. Maraganore has stated that the company aims to address what he described as a lack of funding for prevention in healthcare, and that the pricing of such a drug must be "commensurate with a prevention paradigm," in the hundreds rather than thousands of dollars per year)Skip. He has also discussed the challenges of the current funding environment for biotech, calling it "the most challenging time" he has seen in nearly 40 years in the industry. Maraganore has been a vocal commentator on policy issues affecting the industry. He has expressed concern about the potential impact of the Biosecure Act, stating that nationalizing the supply chain could "cost the industry billions of dollars" and take decades. He has also criticized the Inflation Reduction Act (IRA), calling it "an unfortunate piece of legislation" that will alter the dynamics of partnering and M&A. Maraganore has emphasized the need for a strong and stable FDA, and has spoken about the importance of maintaining U.S. leadership in biomedical innovation, noting that for the first time, Chinese academic papers have exceeded those from U.S. institutions.

Recent appearances

Notable quotes

“The policy environment needs to be a more favorable environment for the future success of our industry — some policies are frankly unhelpful and could erode U.S. leadership in biotechnology globally.”

“I actually think mRNA vaccines are a remarkable innovation — they saved us from the pandemic. It's a little bit sad to see political backlash against them that is unfounded scientifically, but this too shall turn around.”

“We're able to fund this level of work ourselves and we don't take that for granted — we're doing it because we believe in the mission, though this is just the beginning and we'll bring in venture and crossover investors later. At Alnylam we raised $7.5 billion over 20 years, so we know we will need additional capital and partners as we scale.”

“There's no doubt this is one of the toughest environments for fundraising we've seen in the industry, arguably ever. But that raised bar can be a positive — it concentrates talent and forces founders to be much sharper about value‑creation and business plans.”

“I am passionate on this topic. I think that it's the wonderful thing we have created here in R&D discovery and then commercialization of breakthroughs and innovation and I believe that we have a system that works, that's been working. Hatch-Waxman specifically ensures that the drugs that we create today are ultimately free for our kids and for our kids' kids and that is because we have a limited period of time to rea”

“We have to as a society we have to say do we just want to let people die and you know die a miserable death. I think our society would say no, we can't let that happen. So how do we think about the value that's being delivered with the new medicine in relationship to the overall costs that are being averted and how do we think about that at a population level because obviously you have a given payer that has a given ”

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →